Clostridium difficile: recent epidemiologic findings and advances in therapy (Q36861661)

16 August 2017

1 reference

title

Clostridium difficile: recent epidemiologic findings and advances in therapy (English)

1 reference

16 August 2017

main subject

Clostridium difficile

0 references

author name string

Nicole L McMaster-Baxter

series ordinal

1 reference

16 August 2017

Daniel M Musher

series ordinal

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

1029-1039

1 reference

Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Clostridium difficile associated diarrhoea: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Protecting against Clostridium difficile illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Active and passive immunization against Clostridium difficile diarrhea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Nosocomial acquisition of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

The incidence of Clostridium difficile-associated and non-C. difficile-associated diarrhea after use of gatifloxacin and levofloxacin in an acute-care facility

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Clostridium difficile-associated diarrhea in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Clinical practice. Antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Clostridium difficile in a geriatric unit: a prospective epidemiological study employing a novel S-layer typing method

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Practice guidelines for the management of infectious diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Clostridium difficile--Associated diarrhea: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Clostridium difficile infection in patients with unexplained leukocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Clostridium difficile colitis: an efficient clinical approach to diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Oral vancomycin for antibiotic-associated pseudomembranous colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Treatment of Clostridium difficile-associated disease: old therapies and new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Toxic megacolon complicating pseudomembranous enterocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

In vitro and in vivo activities of nitazoxanide against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Nitazoxanide for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

In vitro activity of OPT-80 against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Laparotomy for fulminant pseudomembranous colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Factors associated with failure of metronidazole in Clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1029

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.7.1029

1 reference

16 August 2017

1 reference